The effect of JAK-inhibitors (JAKi) on CD4+ cells was studied using cross-sectional transcriptome of JAKi-treated (n = 24) and untreated RA patients (n = 9) (Supporting Figure S1A). This evidence concerns the gene CD4 and rheumatoid arthritis.